Brief: Sab Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation To Sab-176 Influenza Immunotherapy
18/04/2023 13:31
April 18 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS ANNOUNCES U.S. FDA GRANTS BREAKTHROUGH
THERAPY DESIGNATION TO SAB-176 INFLUENZA IMMUNOTHERAPY
* SAB BIOTHERAPEUTICS ANNOUNCES U.S. FDA GRANTS BREAKTHROUGH
THERAPY DESIGNATION TO SAB-176 INFLUENZA IMMUNOTHERAPY
* SAB BIOTHERAPEUTICS INC - SAB-176 HAS NOW RECEIVED BOTH
BREAKTHROUGH AND FAST TRACK DESIGNATIONS FROM FDA
* SAB BIOTHERAPEUTICS INC - INFLUENZA THERAPEUTIC NOW
ELIGIBLE FOR
INTENSIVE GUIDANCE FROM FDA FOR AN EFFICIENT DEVELOPMENT PROGRAM
Source text for Eikon: ID:nGNX30FV4z
Further company coverage: SABS.O
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies